




(51) International Patent Classification 6 : C07D 487/04, 471/04, A61K 31/495, 31/44		A1	(11) International Publication Number: WO 99/28322 (43) International Publication Date: 10 June 1999 (10.06.99)
(21) International Application Number: PCT/SE98/02091		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 18 November 1998 (18.11.98)			
(30) Priority Data: 9704404-4 28 November 1997 (28.11.97) SE			
(71) Applicant (<i>for all designated States except US</i>): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).			
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): AMIN, Kosrat [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). DAHLSTRÖM, Mikael [FI/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). NORDBERG, Peter [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). STARKE, Ingemar [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE).		Published <i>With international search report.</i>	
(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).			

(54) Title: HETEROCYCLIC COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF

(57) Abstract

The present invention relates to heterocyclic compounds of formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HETERO CYCLIC COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION,
PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL
COMPOSITIONS THEREOF

5 TECHNICAL FIELD

The present invention relates to novel compounds, and therapeutically acceptable salts thereof, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

10 In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a therapeutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

15

BACKGROUND ART

Substituted imidazo[1,2-a] pyrazines are disclosed in EP-A-0068378, US 4,507,294 and EP-A-0204285. Pyrrolo[2,3-d]pyridazines are disclosed in WO 91/17164, WO 92/06979, 20 WO 93/08190 and WO 95/19980. Pyrrolo[1,2-a]pyrazines are disclosed in US 5,041,442.

Benzimidazole and imidazo pyridine derivatives, in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, and which are effective as inhibitors of the gastrointestinal H⁺, K⁺-ATPase, are disclosed in the International Patent Application PCT/SE97/00991 (filing date: 5 June 1997) and in the Swedish Patent Application No. 25 9700661-3 (filing date: 25 February 1997), respectively.


For a review of the pharmacology of the gastric acid pump (the H⁺, K⁺-ATPase), see Sachs et al. (1995) Annu. Rev. Pharmacol. Toxicol. 35: 277-305.

DISCLOSURE OF THE INVENTION

It has surprisingly been found that compounds of the Formula I, which are substituted heterocyclic compounds in which the phenyl moiety is substituted with lower (C_1-C_6) alkyl in 2- and 6-position, are particularly effective as inhibitors of the gastrointestinal H^+-K^+ -ATPase and thereby as inhibitors of gastric acid secretion.

In one aspect, the invention thus relates to compounds of the general Formula I:

10




wherein

15 R¹ is C_1-C_6 alkyl;


R² is C_1-C_6 alkyl;

R³ is H or halogen; and

20




is a substituted heterocycle selected from




5

(imidazo[1,2-a]pyrazine)




(pyrrolo[2,3-d]pyridazine)




(pyrrolo[2,3-b]pyridine)

10



(pyrrolo[1,2-a]pyrazine)



5 wherein

R^4 is H, CH_3 , CH_2OH or CH_2CN ;

R^5 is H or C_1-C_6 alkyl;

10

R^6 is H, C_1-C_6 alkyl, aryl, arylalkyl containing 1-2 carbon atoms in the alkyl part, C_2-C_6 alkenyl, halo(C_2-C_6 alkenyl), C_2-C_6 alkynyl, C_3-C_7 cycloalkyl or halo(C_1-C_6 alkyl);

R^7 is H, halogen, C_1-C_6 alkyl, C_1-C_6 alkylthio or thiocyano;

15

n is 0 or 1; and

X is NH or O.



20 Preferred compounds according to the invention are those wherein:

R^1 is CH_3 or CH_2CH_3 ;

R² is CH₃ or CH₂CH₃; and

R³ is H, Br, Cl or F.

5 Other preferred compounds according to the invention are:



10

wherein R⁴ is CH₃ or CH₂OH; and

X, n, R¹, R², R³, R⁵, R⁶ and R⁷ are as defined for Formula I. Particularly preferred are those compounds wherein R¹, R² and R³ are the preferred substituents defined above.

As used herein, the term "C₁-C₆ alkyl" denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said lower alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.

5

The term "halogen" includes fluoro, chloro, bromo and iodo.

Both the pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers are within the scope of the invention. It should be understood that all the diastereomeric forms 10 possible (pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers) are within the scope of the invention. Also included in the invention are derivatives of the compounds of the Formula I which have the biological function of the compounds of the Formula I.

15 Depending on the process conditions the end products of the Formula I are obtained either in neutral or salt form. Both the free base and the salts of these end products are within the scope of the invention.

20 Acid addition salts of the new compounds may in a manner known *per se* be transformed into the free base using basic agents such as alkali or by ion exchange. The free base obtained may also form salts with organic or inorganic acids.

In the preparation of acid addition salts, preferably such acids are used which form suitably 25 therapeutically acceptable salts. Examples of such acids are hydrohalogen acids such as hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxyl or sulphonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybensoic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, halogenbensesulfonic acid, toluenesulfonic acid or naphthalenesulfonic acid.

Preparation

The present invention also provides the following processes A and B for the manufacture of compounds with the general Formula I.


5

Process A


Process A for manufacture of compounds with the general Formula I comprises the following steps:

10

Compounds of the general Formula II



15 wherein X¹ is OH or NH₂, can be reacted with compounds of the general Formula III



wherein R¹, R³ and R⁴ are as defined for Formula I and Y¹ is a leaving group, such as a
20 halide, tosyloxy or mesyloxy, to the compounds of the Formula I.

It is convenient to conduct this reaction in an inert solvent, e.g. acetone, acetonitrile, dimethoxyethane, methanol, ethanol, xylene or dimethylformamide with or without a base.


The base is e.g. an alkali metal hydroxide, such as sodium hydroxide and potassium hydroxide; a sodium alcoholate, such as sodium methoxide and sodium ethoxide; an alkali metal hydride such as sodium hydride and potassium hydride; an alkali metal carbonate, such as potassium carbonate and sodium carbonate; or an organic amine, such as triethylamine.

5

Process B


Process B for manufacture of compounds with the general Formula I comprises the
10 following steps:

Compounds of the general Formula IV



15

wherein X^2 is a leaving group e.g. halide, can be reacted with compounds of the general
Formula V



20

wherein R^1 , R^3 and R^4 are as defined for Formula I and Y^2 is NH_2 or OH to compounds
of the general Formula I.

It is convenient to conduct this reaction in an inert solvent, e.g. acetone, acetonitrile, dimethoxyethane, methanol, ethanol, xylene or dimethylformamide with or without a base. The base is e.g. an alkali metal hydroxide, such as sodium hydroxide and potassium hydroxide; a sodium alcoholate, such as sodium methoxide and sodium ethoxide; an alkali metal hydride such as sodium hydride and potassium hydride; an alkali metal carbonate, such as potassium carbonate and sodium carbonate; or an organic amine, such as triethylamine.

Pharmaceutical formulations

10

In yet a further aspect, the invention relates to pharmaceutical compositions containing at least one compound of the invention, or a therapeutically acceptable salt thereof, as active ingredient.

15

The compounds of the invention can also be used in formulations together with other active ingredients, e.g. antibiotics such as amoxicillin.

20

For clinical use, the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration. The pharmaceutical formulation contains a compound of the invention in combination with one or more pharmaceutically acceptable ingredients. The carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compounds is between 0.1–95% by weight of the preparation, preferably between 0.1–20% by weight in preparations for parenteral use and preferably between 0.1 and 50% by weight in preparations for oral administration.

25

In the preparation of pharmaceutical formulations containing a compound of the present invention in the form of dosage units for oral administration the compound selected may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as

with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or pressed into tablets.

- 5 Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain granules of the active compound. Hard gelatine capsules may also contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato
10 starch, corn starch, amylopectin, cellulose derivatives or gelatine.

Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable
15 oil, paraffin oil or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.

Liquid preparations for oral administration may be prepared in the form of syrups or
20 suspensions, e.g. solutions or suspensions containing from 0.1% to 20% by weight of the active ingredient and the remainder consisting of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral
25 administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.

Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent, preferably in a concentration from
30 0.1% to 10% by weight. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials.

Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.

The typical daily dose of the active substance varies within a wide range and will depend
5 on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 1000 mg per day of active substance.


The compounds according to the invention can also be used in formulations together with
10 other active ingredients, e.g. for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa. Such other active ingredients may be antimicrobial agents, in particular:

- b-lactam antibiotics such as amoxicillin, ampicillin, cephalothin, cefaclor or cefixime;
- macrolides such as erythromycin, or clarithromycin;
- 15 – tetracyclines such as tetracycline or doxycycline;
- aminoglycosides such as gentamycin, kanamycin or amikacin;
- quinolones such as norfloxacin, ciprofloxacin or enoxacin;
- others such as metronidazole, nitrofurantoin or chloramphenicol; or
- preparations containing bismuth salts such as bismuth subcitrate, bismuth subsalicylate,
20 bismuth subcarbonate, bismuth subnitrate or bismuth subgallate.

EXAMPLES


Example 1.1

- 5 *Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)imidazo [1,2-a]pyrazine*



A stirred mixture of 8-chloro-2,3-dimethylimidazo[1,2-a]pyrazine (0.5 g, 2.8 mmol) and
10 2,6-dimethylbenzylamin (0.41 g, 3.0 mmol) in xylene (10 ml) was refluxed for 24 h. The mixture was evaporated under reduced pressure, dissolved in methylene chloride (20 ml) and was washed with a solution of 5% sodium carbonate in water (20 ml). The organic layer was separated and evaporated under reduced pressure and the residue was purified by column chromatography on silica gel. Crystallization from pentane gave 90 mg (23%) of
15 the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 2.35 (s, 6H), 2.45 (s, 6H), 4.70(d, 2H), 5.60 (bs, 1H), 7.05-7.20 (m, 3H), 7.25 (d, 1H), 7.40 (d, 1H)

*Example 1.2**Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzyloxy)imidazo[1,2-a]pyrazine*

5

Sodium hydride (0.15 g, 3 mmol) (50 % in oil) was added to a stirred solution of 2,6-dimethylbenzylalcohol in acetonitril (10 ml). 8-chloro-2,3-dimethylimidazo[1,2-a]pyrazine (0.4 g, 3 mmol) was added and the reaction mixture was refluxed for 20 h. The solvent was evaporated under reduced pressure and the residue was solved in methylene chloride and washed with water. The organic layer was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using ethylacetate:petroleum ether(40-60) 1:1 as eluent. Crystallization from petroleum ether gave 0.42 g (50 %) of the title compound.

15

¹H-NMR (300 MHz, CDCl₃): δ 2.35 (s, 3H), 2.40 (s, 3H), 2.45 (s, 6H), 5.6 (s, 2H) 6.95-7.15 (m, 3H), 7.35-7.45 (m 2H)

BIOLOGICAL TESTS

*1. In vitro experiments*5 *Acid secretion inhibition in isolated rabbit gastric glands*

Inhibiting effect on acid secretion *in vitro* in isolated rabbit gastric glands was measured as described by Berglindh et al. (1976) Acta Physiol. Scand. 97, 401-414.

10 *Determination of H⁺,K⁺-ATPase activity*

Membrane vesicles (2.5 to 5 µg) were incubated for 15 min at +37°C in 18 mM Pipes/Tris buffer pH 7.4 containing 2 mM MgCl₂, 10 mM KCl and 2 mM ATP. The ATPase activity was estimated as release of inorganic phosphate from ATP, as described by LeBel et al. 15 (1978) Anal. Biochem. 85, 86-89.

The compound of Example 1 had an IC₅₀ value of 0.16 µM and the compound of Example 2 had an IC₅₀ value of 2.78 µM.

20 *2. In vivo experiments**Inhibiting effect on acid secretion in female rats*

Female rats of the Sprague-Dawly strain are used. They are equipped with cannulated 25 fistulae in the stomach (lumen) and the upper part of the duodenum, for collection of gastric secretions and administration of test substances, respectively. A recovery period of 14 days after surgery is allowed before testing commenced.

Before secretory tests, the animals are deprived of food but not water for 20 h. The stomach 30 is repeatedly washed through the gastric cannula with tap water (+37°C), and 6 ml Ringer-Glucose given subcutaneously. Acid secretion is stimulated with infusion during 2.5-4 h

- (1.2 ml/h, subcutaneously) of pentagastrin and carbachol (20 and 110 nmol/kg·h, respectively), during which time gastric secretions are collected in 30-min fractions. Test substances or vehicle are given either at 60 min after starting the stimulation (intravenous and intraduodenal dosing, 1 ml/kg), or 2 h before starting the stimulation (oral dosing, 5 ml/kg, gastric cannula closed). The time interval between dosing and stimulation may be increased in order to study the duration of action. Gastric juice samples are titrated to pH 7.0 with NaOH, 0.1 M, and acid output calculated as the product of titrant volume and concentration.
- 10 Further calculations are based on group mean responses from 4-6 rats. In the case of administration during stimulation; the acid output during the periods after administration of test substance or vehicle are expressed as fractional responses, setting the acid output in the 30-min period preceding administration to 1.0. Percentage inhibition is calculated from the fractional responses elicited by test compound and vehicle. In the case of administration 15 before stimulation; percentage inhibition is calculated directly from acid output recorded after test compound and vehicle.

Bioavailability in rat

- 20 Adult rats of the Sprague-Dawley strain are used. One to three days prior to the experiments all rats are prepared by cannulation of the left carotid artery under anaesthesia. The rats used for intravenous experiments are also cannulated in the jugular vein (Popovic (1960) J. Appl. Physiol. 15, 727-728). The cannulas are exteriorized at the nape of the neck.
- 25 Blood samples (0.1 - 0.4 g) are drawn repeatedly from the carotid artery at intervals up to 5.5 hours after given dose. The samples are frozen until analysis of the test compound.
- 30 Bioavailability is assessed by calculating the quotient between the area under blood/plasma concentration (AUC) curve following (i) intraduodenal (i.d.) or oral (p.o.) administration and (ii) intravenous (i.v.) administration from the rat or the dog, respectively.

The area under the blood concentration vs. time curve, AUC, is determined by the log/linear trapezoidal rule and extrapolated to infinity by dividing the last determined blood concentration by the elimination rate constant in the terminal phase. The systemic bioavailability (F%) following intraduodenal or oral administration is calculated as

5 $F(\%) = (\text{AUC (p.o. or i.d.)} / \text{AUC (i.v.)}) \times 100.$

Inhibition of gastric acid secretion and bioavailability in the conscious dog.

10 Labrador retriever or Harrier dogs of either sex are used. They are equipped with a duodenal fistula for the administration of test compounds or vehicle and a cannulated gastric fistula or a Heidenhaim-pouch for the collection of gastric secretion.


15 Before secretory tests the animals are fasted for about 18 h but water is freely allowed. Gastric acid secretion is stimulated for up to 6.5 h infusion of histamine dihydrochloride (12 ml/h) at a dose producing about 80% of the individual maximal secretory response, and gastric juice collected in consecutive 30-min fractions. Test substance or vehicle is given orally, i.d. or i.v., 1 or 1.5 h after starting the histamine infusion, in a volume of 0.5 ml/kg body weight. In the case of oral administration, it should be pointed out that the test
20 compound is administered to the acid secreting main stomach of the Heidenham-pouch dog.

The acidity of the gastric juice samples are determined by titration to pH 7.0, and the acid output calculated. The acid output in the collection periods after administration of test
25 substance or vehicle are expressed as fractional responses, setting the acid output in the fraction preceding administration to 1.0. Percentage inhibition is calculated from fractional responses elicited by test compound and vehicle.

Blood samples for the analysis of test compound concentration in plasma are taken at intervals up to 4 h after dosing. Plasma is separated and frozen within 30 min after collection and later analyzed. The systemic bioavailability (F%) after oral or i.d. administration is calculated as described above in the rat model.

CLAIMS

1. A compound of the formula I



5

or a pharmaceutically acceptable salt thereof, wherein


R¹ is C₁-C₆ alkyl;

10




R² is C₁-C₆ alkyl;

R³ is H or halogen; and



15



is a substituted heterocycle selected from




5



or

10



wherein

5 R⁴ is H, CH₃, CH₂OH or CH₂CN;

R⁵ is H or C₁-C₆ alkyl;

10 R⁶ is H, C₁-C₆ alkyl, aryl, arylalkyl containing 1-2 carbon atoms in the alkyl part, C₂-C₆ alkenyl, halo(C₂-C₆ alkenyl), C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or halo(C₁-C₆ alkyl);


R⁷ is H, halogen, C₁-C₆ alkyl, C₁-C₆ alkylthio or thiocyanato;

n is 0 or 1; and

15


X is NH or O.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof,
wherein




20

is




wherein R⁴, R⁵ and X are as defined in claim 1.

3. A compound according to claim 1, or a pharmaceutically acceptable salt thereof,
5 wherein




is




wherein R⁴, R⁶ and X are as defined in claim 1.

10

4. A compound according to claim 1, or a pharmaceutically acceptable salt thereof,
wherein




is




wherein R⁴, R⁵, R⁶ and X are as defined in claim 1.

5. A compound according to claim 1, or a pharmaceutically acceptable salt thereof,
wherein




is




wherein R⁴, R⁵, R⁷ and X are as defined in claim 1.

10

6. A compound according to claim 1, or a pharmaceutically acceptable salt thereof,
wherein




is




wherein R⁴, R⁵ and X are as defined in claim 1.

7. A compound according to claim 1, or a pharmaceutically acceptable salt thereof,
5 wherein




is



wherein R⁴ and X are as defined in claim 1.


10

8. A compound according to claim 1, or a pharmaceutically acceptable salt thereof,
wherein R¹ and R² are independently CH₃ or CH₂CH₃.
9. A compound according to claim 2 which is the compound 2,3-dimethyl-8-(2,6-
15 dimethylbenzylamino)imidazo [1,2-a]pyrazine




or a pharmaceutically acceptable salt thereof.

- 5 10. The compound according to claim 2 which is the compound 2,3-dimethyl-8-(2,6-dimethylbenzyloxy)imidazo[1,2-a]pyrazine




or a pharmaceutically acceptable salt thereof.

- 10 11. A process for the preparation of a compound according to any one of claims 1 to 10, comprising reacting a compounds of the general Formula II



wherein X^1 is OH or NH₂, with a compound of the general Formula III




5

wherein R¹, R³ and R⁴ are as defined for Formula I and Y¹ is a leaving group.


12. A process for the preparation of a compound according to any one of claims 1 to 10, comprising reacting a compounds of the general Formula IV

10



wherein X² is a leaving group, with a compound of the general Formula V

15



wherein R¹, R³ and R⁴ are as defined for Formula I, and Y² is NH₂ or OH.

13. A compound according to any one of claims 1 to 10 for use in therapy.
14. A pharmaceutical formulation containing a compound according to any one of claims 1 to 10 as active ingredient in combination with a pharmaceutically acceptable diluent or carrier.
5
15. Use of a compound according to any one of claims 1 to 10 for the manufacture of a medicament for the inhibition of gastric acid secretion.
10
16. Use of a compound according to any one of claims 1 to 10 for the manufacture of a medicament for the treatment of gastrointestinal inflammatory diseases.
15
17. Use of a compound according to any one of claims 1 to 10 the manufacture of a medicament for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, wherein the said salt is adapted to be administered in combination with at least one antimicrobial agent.
20
18. A method for inhibiting gastric acid secretion which comprises administering to a mammal, including man, in need of such inhibition an effective amount of a compound according to any one of claims 1 to 10.
25
19. A method for the treatment of gastrointestinal inflammatory diseases which comprises administering to a mammal, including man, in need of such treatment an effective amount of a compound according to any one of claims 1 to 10.
30
20. A method for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, which comprises administering to a mammal, including humans, in need of such treatment an effective amount of a compound as claimed in any one of claims 1 to 10, wherein the said salt is administered in combination with at least one antimicrobial agent.

21. A pharmaceutical formulation for use in the inhibition of gastric acid secretion wherein the active ingredient is a compound according to any one of claims 1 to 10.
22. A pharmaceutical formulation for use in the treatment of gastrointestinal inflammatory diseases wherein the active ingredient is a compound according to any one of claims 1 to 10.
23. A pharmaceutical formulation for use in the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, wherein the active ingredient is a compound according to any one of claims 1 to 10 in combination with at least one antimicrobial agent.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/02091

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 487/04, C07D 471/04, A61K 31/495, A61K 31/44
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0068378 A1 (SCHERING CORPORATION), 5 January 1983 (05.01.83), page 30, line 1 - page 32, line 12; page 43, line 6 - page 46, line 24, the claims --	1-23
X	US 4507294 A (JAMES A. BRISTOL ET AL), 26 March 1985 (26.03.85), column 21, line 5 - line 30, the claims --	1-23
X	EP 0204285 A1 (FUJISAWA PHARMACEUTICAL CO., LTD.), 10 December 1986 (10.12.86), the claims --	1-23

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

2 March 1999

Date of mailing of the international search report

17-03-1999

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer
Gerd Strandell
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/02091

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0742218 A1 (SANKYO COMPANY LIMITED), 13 November 1996 (13.11.96) --	1-23
X	US 5041442 A (RUTH S. ROMERO ET AL), 20 August 1991 (20.08.91) --	1-23
X	WO 9308190 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 29 April 1993 (29.04.93) --	1-23
X	WO 9206979 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 30 April 1992 (30.04.92) --	1-23
X	WO 9117164 A1 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH), 14 November 1991 (14.11.91) --	1-23
X	J. Med. Chem., Volume 40, No 4, 1997, James J. Kaminski et al, "Antiulcer Agents. 6. Analysis of the in Vitro Biochemical and in Vivo Gastric Antisecretory Activity of Substituted Imidazo(1,2-alpha)pyridines and Related Analogues Using Comparative Molecular Field Analysis...." page 427 - page 436 -- -----	1-23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/02091

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 18-20
because they relate to subject matter not required to be searched by this Authority, namely:

Claims 18-20 relate to methods of treatment of the human or animal body by surgery or by therapy. See PCT, Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest



The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

02/02/99

PCT/SE 98/02091

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0068378 A1	05/01/83	SE 0068378 T3 AT 18402 T AU 556062 B AU 8517882 A CA 1248957 A DK 284482 A FI 73433 B,C FI 822266 A GR 74924 A IE 53324 B JP 1718718 C JP 4004318 B JP 58013584 A OA 7130 A PT 75115 B US 4450164 A ZA 8204516 A CA 1202630 A US 4507294 A		15/03/86 23/10/86 06/01/83 17/01/89 27/12/82 30/06/87 27/12/82 12/07/84 12/10/88 14/12/92 27/01/92 26/01/83 31/03/84 28/06/85 22/05/84 29/02/84 01/04/86 26/03/85
US 4507294 A	26/03/85	AT 18402 T AU 556062 B AU 8517882 A CA 1202630 A DK 284482 A EP 0068378 A,B SE 0068378 T3 FI 73433 B,C FI 822266 A GR 74924 A IE 53324 B OA 7130 A PT 75115 B US 4450164 A		15/03/86 23/10/86 06/01/83 01/04/86 27/12/82 05/01/83 30/06/87 27/12/82 12/07/84 12/10/88 31/03/84 28/06/85 22/05/84
EP 0204285 A1	10/12/86	AU 593802 B AU 5834586 A CA 1257264 A DE 3683403 A DK 250386 A FI 862210 A GR 861379 A JP 62016483 A US 4725601 A EP 0228006 A JP 62187471 A US 4782055 A		22/02/90 11/12/86 11/07/89 27/02/92 05/12/86 05/12/86 28/08/86 24/01/87 16/02/88 08/07/87 15/08/87 01/11/88

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/02/99

International application No.

PCT/SE 98/02091

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0742218 A1	13/11/96	AU 680998 B AU 1465795 A FI 962892 A NO 962998 A CA 2181553 A CN 1143964 A CZ 283216 B CZ 9602084 A HU 9601967 D JP 7247285 A NZ 278675 A WO 9519980 A		14/08/97 08/08/95 16/09/96 17/09/96 27/07/95 26/02/97 18/02/98 11/12/96 00/00/00 26/09/95 27/07/97 27/07/95
US 5041442 A	20/08/91	NONE		
WO 9308190 A1	29/04/93	AU 2870492 A EP 0609328 A JP 7500329 T US 5534515 A		21/05/93 10/08/94 12/01/95 09/07/96
WO 9206979 A1	30/04/92	AU 8712191 A		20/05/92
WO 9117164 A1	14/11/91	AU 7754691 A CN 1056102 A PT 97467 A		27/11/91 13/11/91 31/01/92